Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBT (2021 - 2025)

Historic EBT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $7.5 million.

  • Arcutis Biotherapeutics' EBT rose 11803.21% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.3 million, marking a year-over-year increase of 7781.6%. This contributed to the annual value of -$139.4 million for FY2024, which is 4618.63% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' EBT stood at $7.5 million, which was up 11803.21% from -$15.5 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' EBT's 5-year high stood at $7.5 million during Q3 2025, with a 5-year trough of -$107.7 million in Q3 2022.
  • Over the past 5 years, Arcutis Biotherapeutics' median EBT value was -$52.3 million (recorded in 2024), while the average stood at -$50.0 million.
  • In the last 5 years, Arcutis Biotherapeutics' EBT crashed by 8870.49% in 2022 and then skyrocketed by 11803.21% in 2025.
  • Arcutis Biotherapeutics' EBT (Quarter) stood at -$71.3 million in 2021, then fell by 1.03% to -$72.0 million in 2022, then rose by 8.0% to -$66.3 million in 2023, then skyrocketed by 84.21% to -$10.5 million in 2024, then surged by 171.57% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, -$15.5 million for Q2 2025, and -$24.8 million during Q1 2025.